Stock Screener App

무료 -

3.49

0.29% +0.01

큐어백 (CVAC)

개요 뉴스 가격 이력 옵션 체인 CVAC 왜 하락? 토론 예측

CureVac N.V. 주식(CVAC)의 최신 뉴스

CureVac (NASDAQ:CVAC) Shares Gap Up to $3.48 - MarketBeat

CVAC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

The InvestChronicle

CureVac N.V. (CVAC)'s stock price range in the last year – US Post News - US Post News

CureVac (NASDAQ:CVAC) Shares Up 5.5% - MarketBeat

mRNA Therapeutics Market is estimated to Grow at Massive CAGR of +17% by 2031 | Moderna Inc., BioNTech SE ... - openPR

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates - Yahoo Finance

Market Resilience: CureVac N.V. (CVAC) Finishes Strong/Weak at 2.331, Up 0.87 – DWinneX - The Dwinnex

COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle - Cure - Benzinga

Curevac's Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability - TipRanks.com - TipRanks

CureVac Names New Chief Business Officer - TipRanks.com - TipRanks

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update - wallstreet:online

wallstreet:online

CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual ... - Yahoo Finance

Curevac and MD Anderson collaborate to develop mRNA-based cancer vaccines - BioWorld Online

BioWorld Online

CureVac and MD Anderson partner on mRNA cancer vaccines - Investing.com Nigeria

Investing.com Nigeria

CureVac's Influenza Vaccine Shows Strong Phase 2 Results - TipRanks.com - TipRanks

CureVac, GSK Partner Release Data On Influenza Vaccine Study - CureVac (NASDAQ:CVAC), GSK (NYSE:GSK) - Benzinga

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully - Simply Wall St

CureVac: No Momentum In Sight (NASDAQ:CVAC) - Seeking Alpha

CVAC Stock Quote Price and Forecast - CNN

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

Zacks Investment Research

Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC) - Yahoo Finance

Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)

Zacks Investment Research

CureVac announces positive Phase II Covid-19 vaccine trial data - Clinical Trials Arena

Clinical Trials Arena

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration ... - Yahoo Finance

These Analysts Just Made A Huge Downgrade To Their CureVac N.V. (NASDAQ:CVAC) EPS Forecasts - Yahoo Finance

Factbox: Companies developing mRNA treatments and vaccines - Reuters

Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday

German patent court deals CureVac a blow to Covid vaccine IP - Boston Business Journal

Boston Business Journal

Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research

CureVac Earnings: Early-Stage Pipeline Makes Progress; Shares Undervalued for Long-Term Investors - Morningstar

Acuitas sues CureVac for credit on COVID-19 vaccine patents - ETHealthWorld

Acuitas Sues Partner CureVac for Vaccine-Tech Patents Share (1) - Bloomberg Law

CureVac to Report Third Quarter and First Nine Months 2023 Financial Results and Business Updates on November ... - CureVac

Why CureVac Stock Plunged Today - The Motley Fool

The Motley Fool

CureVac touts 'progress' in vaccine patent case against BioNTech - FiercePharma

CureVac highlights shift in seasonal influenza vaccines development pipeline - Clinical Trials Arena

Clinical Trials Arena

Dr. Franz Haas to Step Down as CEO of CureVac N.V. - Contract Pharma

Contract Pharma

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates - Simply Wall St

CureVac Earnings: Early-Stage mRNA Pipeline Makes Progress; Shares Undervalued - Morningstar

CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update - CureVac

Further weakness as CureVac (NASDAQ:CVAC) drops 9.7% this week, taking one-year losses to 40% - Yahoo Finance

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates ... - Yahoo Finance

CureVac turns up the heat in ongoing patent litigation with Pfizer - Pharmaceutical Technology

Pharmaceutical Technology

CureVac puts more patent claims on the table in its COVID-19 vaccine suits against Pfizer and BioNTech - FiercePharma

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma - Yahoo Finance

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update - CureVac

CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology - Reuters

GSK, CureVac initiate new Phase I/II trial of mRNA flu vaccine - Clinical Trials Arena

Clinical Trials Arena

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares - CureVac

$77.56

0.77%

$149.40

1.20%

$29.98

1.11%

$172.85

1.06%

$365.81

2.87%

$90.61

2.55%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기